Skip to content

About Us

We are SK Life Science, a pharmaceutical company changing the future of CNS and oncology treatment.

SK Life Science is a subsidiary of SK Biopharmaceuticals, a company focused on developing innovative, next-generation drugs. Both are a part of SK Group, a global conglomerate headquartered in Korea, a leader in energy, chemical, semiconductor and telecommunications industries, and one of TIME’s 100 Most Influential Companies of 2023.

Our Purpose

We believe there is more to life when you connect health with happiness.

Values Define Us

At SK Life Science, our work is guided by our core values. Together, we…

  • Empower Excellence
  • Are Fully Engaged
  • Appreciate and Recognize People
  • Embody A Pioneering Spirit
  • Always Do The Right Thing
  • Inspire Happiness!

We are committed to the patient communities we serve.

We are proud to be the first Korea-based company to discover, develop and commercialize a molecule from inception through FDA approval without partnering or out-licensing.
We have 30 years of experience in R&D and are dedicated to changing the status quo in the treatment of CNS disorders and cancer.
We currently have 8 compounds in the clinical development pipeline.

SK Life Science: A History of Discovery

SK Life Science is a subsidiary of SK Biopharmaceuticals. Together, we are focused on developing innovative, next-generation drugs. Both are part of SK Group, a global conglomerate headquartered in Korea.

Select A Year


Research and development of new medicines begins

A Global Presence

SK Life Science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and a part of SK Group—a global conglomerate investing in game-changing businesses in industries that include life sciences, semiconductors, and sustainable energy.


SK: Our parent company’s global reach

SK Biopharmaceuticals: Gyeonggi, South Korea.
Learn about our global headquarters.

SK Life Science: A subsidiary of SK Biopharmaceuticals, Paramus, NJ, USA

Our Focus

Commercialization of meaningful products for the treatment of CNS disorders and oncology.

SK Group Key Facts

Second largest conglomerate in Korea (2021)1
Founded in 1953 (textiles)2
SK is investing more than $50 billion in U.S. businesses
SK is ranked #129 on the Fortune Global 500
Number of global partners and affiliates2

Select A Year for Details


Established Sunkyoung Textiles

Our Goal

Become a global leader in the development of treatments that will help patients living with CNS disorders and cancer.


Pushing innovation forward together

Because more can be done when people come together, we seek partnerships with universities, government organizations, and pharmaceutical and biotech companies across multiple therapeutic areas.

Since 2018, SK Life Science has been working with patient and advocacy groups who share our mission to change the future of CNS care.

We are proud to support people living with epilepsy, as well as their families and loved ones, through our numerous collaborations. Please visit these organizations to empower yourself with the tools you need to achieve health and happiness.

Select A Relevant disorder for quick facts

  • Around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. 3
  • An estimated 3 million adults and 470,000 children live with epilepsy in the U.S.4
  • Lennox-Gastaut Syndrome (LGS) is a severe and rare form of childhood-onset epilepsy.
  • It is estimated that LGS affects approximately 1 to 2 per million individuals, accounting for less than 5% of all childhood epilepsy cases.5
  • In the U.S. alone, it’s estimated that at least 25 million adults have obstructive sleep apnea (OSA).6
  • Prevalence of obstructive sleep apnea with daytime sleepiness has been shown to increase with body mass index, in adults aged 50 to 70 years (8% to 43% in men; 3% to 21% in women).7
  • Neuropathic pain has been reported to occur in about 1 in every 10 adults over age 30.8
  • The high degree of patient burden associated with neuropathic pain is often associated with poor function, compromised health status and sleep, and increased anxiety and depression.9
  • An estimated 6.7 million Americans age 65 and older are living with Alzheimer’s dementia in 2023.10
  • In U.S. adults, lifetime prevalence of any anxiety disorder is 28.8%.11
  • In U.S. adults, the lifetime prevalence of major depressive disorder is 16.6%.11
  • In 2021, an estimated 21.0 million adults in the United States had at least one major depressive episode. This number represented 8.3% of all U.S. adults.12
  • The cost of treatment and loss in productivity associated with schizophrenia are estimated to be more than $60 billion annually in the U.S.13
  • Schizophrenia is one of the top 15 leading causes of disability worldwide.14
  • Across studies that use household-based survey samples, clinical diagnostic interviews, and medical records, estimates of the prevalence of schizophrenia and related psychotic disorders in the U.S. range between 0.25% and 0.64%.14

Ethics & Compliance Program

SK Life Science, Inc. (SKLSI) is committed to conducting business honestly, ethically, and in compliance with laws and regulations

Our goal is to conduct business and promote our products in an informed, compliant manner.

Our program is tailored to meet the standards set forth by the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services in its Compliance Program Guidance for Pharmaceutical Manufacturers, as well as other relevant industry guidance and laws.

SK Life Science is committed to managing an effective compliance program. Our compliance training program requires all employees and contractors to be trained on the Company’s Code of Conduct and a number of policies including those regarding Anti-Bribery/Anti-Corruption, Investigations and Discipline, Healthcare Professionals Interactions, Conflicts of Interests, Travel & Expenses,  Social Media and others, in addition to role-specific trainings.

Policy # Trained
Code of Conduct (annual) 268 (2023)
Anti-Bribery/Anti Corruption 251
Investigations and Discipline 251

The SKLSI Compliance and Ethics Hotline offers employees, business partners, customers, and members of the public the opportunity to report concerns about potential misconduct or unethical behavior. To submit a question or concern, please contact our anonymous hotline at 833-490-0007, or visit or SK Whistleblowing Portal

Company received six reports of potential compliance violations in 2023 across the organization, four of these were unsubstantiated and actions were taken on the other two.

CA Annual Declaration of Compliance

SK Life Science, Inc. has a Comprehensive Compliance Program (CCP) in accordance with the requirements set forth by California Health & Safety Code §§ 119400-119402. To view SKLSI’s declaration of compliance, click the link below:

Anti-Bribery and Anti-Corruption Policy

SK Life Science, Inc. has a policy that establishes the requirement for SKLSI Associates to conduct all business ethically and in accordance with all applicable anti-bribery and anti-corruption (ABAC) laws and regulations in the jurisdictions in which SKLSI does business.

Compliance Concerns:
Compliance Hotline: 1-833-490-0007
SK Whistleblowing Portal*:
*You may remain anonymous.


  1. The Korea Herald. SK Group emerges as No. 2 conglomerate in 2021. Updated February 9, 2022. Accessed August 9, 2023.
  2. Data on file, SK Life Science.
  3. World Health Organization. Key Facts. Accessed August 9, 2023.
  4. Centers for Disease Control and Prevention (CDC). Epilepsy. Epilepsy Fast Facts. Who Has Epilepsy. Active Epilepsy. Accessed August 9, 2023.
  5. NIH. National Library of Medicine. MedlinePlus. Genetics. Genetic Conditions. Lennox-Gastaut syndrome. Accessed August 9, 2023.
  6. American Academy of Sleep Medicine. Rising prevalence of sleep apnea in U.S. threatens public health. Published September 29, 2014. Accessed August 9, 2023.
  7. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013 May 1;177(9):1006-14. doi: 10.1093/aje/kws342. Epub 2013 Apr 14. PMID: 23589584; PMCID: PMC3639722. Accessed August 9, 2023.
  8. Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton LJ 3rd. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. Pain Med. 2009 Apr;10(3):586-93. doi: 10.1111/j.1526-4637.2009.00588.x. Epub 2009 Mar 17. Erratum in: Pain Med. 2011 Aug;12(8):1294. PMID: 20849570; PMCID: PMC2964880. Accessed August 9, 2023.
  9. Schaefer C, Mann R, Sadosky A, et al. Burden of illness associated with peripheral and central neuropathic pain among adults seeking treatment in the United States: a patient-centered evaluation. Pain Med. 2014;15(12):2105-2119. 
  10. 2023 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2023;19(4). DOI 1002/alz.13016. Facts-And-Figures-2023-At-A-Glance-Stats-Fact-Sheet.pdf (
  11. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. Accessed August, 9, 2023.
  12. National Institute of Mental Health. Major Depression. Published January 2022. NIMH » Major Depression ( Accessed August 9, 2023.
  13. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002 [abstract]. J Clin Psychiatry. 2005;66(9):1122-1129. Accessed August 9, 2023.
  14. National Institute of Mental Health. Schizophrenia. NIMH » Schizophrenia ( Accessed August 9, 2023.